Title: Widespread use of proton pump inhibitors or potassium-competitive acid blocker has
changed the status of gastrointestinal bleeding in patients with ischemic heart disease: Real-
world data from high volume centers
Version: 2 Date: 28 Jan 2024
Reviewer:  Yi-Hua Wu
Reviewer's report:
1. This review offers promising prospects, however the authors should provide further details
about the safety of PPI or PCAB in patients undergoing Plavix treatment after PCI for ischemic
heart disease. Due to the possible reduction in effectiveness of Plavix, PPIs may increase the
risk of heart attack or stroke. Additionally, the inclusion of pharmacological side effects, such
as allergic reactions, should be taken into account when determining the exclusion criteria or
secondary outcome measures.
Furthermore, the authors could consider updating the mentioned examples in the paper to include
data from 2022 or 2023, instead of stopping at 2019.
3. It is necessary to establish the categorization of gastric ulcers in patients before to PCI.
4. It is necessary to explain the approach used to address unavailable information.
The authors fail to elucidate their approach in addressing this dearth of information, including
both the main and secondary outcomes.
Title: Widespread use of proton pump inhibitors or potassium-competitive acid blocker has
changed the status of gastrointestinal bleeding in patients with ischemic heart disease: Real-
world data from high volume centers
Version: 2 Date: 28 Jan 2024
Reviewer:  Yi-Hua Wu
Reviewer's report:
1. This review offers promising prospects, however the authors should provide further details
about the safety of PPI or PCAB in patients undergoing Plavix treatment after PCI for ischemic
heart disease. Due to the possible reduction in effectiveness of Plavix, PPIs may increase the
risk of heart attack or stroke. Additionally, the inclusion of pharmacological side effects, such
as allergic reactions, should be taken into account when determining the exclusion criteria or
secondary outcome measures.
Furthermore, the authors could consider updating the mentioned examples in the paper to include
data from 2022 or 2023, instead of stopping at 2019.
3. It is necessary to establish the categorization of gastric ulcers in patients before to PCI.
4. It is necessary to explain the approach used to address unavailable information.
The authors fail to elucidate their approach in addressing this dearth of information, including
both the main and secondary outcomes.
Please review this paper.
user
Title: Widespread use of proton pump inhibitors or potassium-competitive acid blocker has
changed the status of gastrointestinal bleeding in patients with ischemic heart disease: Real-
world data from high volume centers
Version: 2 Date: 28 Jan 2024
Reviewer:  Yi-Hua Wu
Reviewer's report:
1. This review offers promising prospects, however the authors should provide further details
about the safety of PPI or PCAB in patients undergoing Plavix treatment after PCI for ischemic
heart disease. Due to the possible reduction in effectiveness of Plavix, PPIs may increase the
risk of heart attack or stroke. Additionally, the inclusion of pharmacological side effects, such
as allergic reactions, should be taken into account when determining the exclusion criteria or
secondary outcome measures.
Furthermore, the authors could consider updating the mentioned examples in the paper to include
data from 2022 or 2023, instead of stopping at 2019.
3. It is necessary to establish the categorization of gastric ulcers in patients before to PCI.
4. It is necessary to explain the approach used to address unavailable information.
The authors fail to elucidate their approach in addressing this dearth of information, including
both the main and secondary outcomes.
assistant